• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca's 9M and Q3 2024 results

    11/12/24 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum

    AstraZeneca:

    Revenue and EPS summary

     

     

    9M 2024

    % Change

    Q3 2024

    % Change

    $m

    Actual

    CER1

    $m

    Actual

    CER

    - Product Sales

    37,576

    16

    19

    12,947

    18

    20

    - Alliance Revenue

     

    1,498

    49

    50

    559

    48

    50

    - Collaboration Revenue

    108

    (66)

    (66)

    59

    (39)

    (40)

    Total Revenue

     

    39,182

    16

    19

    13,565

    18

    21

    Reported EPS

    $3.57

    11

    21

    $0.92

    4

    17

    Core2 EPS

    $6.12

    5

    11

    $2.08

    20

    27

    Financial performance for 9M 2024 (Growth numbers at constant exchange rates)

    • Total Revenue up 19% to $39,182m, driven by a 19% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines
    • Total Revenue growth from Oncology was 22%, CVRM 21%, R&I 24% and Rare Disease 14%
    • Core Product Sales Gross Margin3 of 82%
    • Core Operating Margin of 32%
    • Core Tax Rate of 20%
    • Core EPS increased 11% to $6.12. In the prior year period, Core EPS included gains totalling $953m from the disposal of Pulmicort Flexhaler US rights and updated contractual arrangements for Beyfortus
    • Guidance for FY 2024 Total Revenue and Core EPS growth at CER upgraded to high teens percentage growth

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

    "Our company has continued on its strong growth trajectory in the first nine months of 2024. Total Revenue and Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to our full year 2024 guidance.

    In the year to date we have announced the results for multiple positive high-value trials and are working to bring these new options to patients as quickly as possible. Additionally, the quality and impact of our scientific research was well recognised this quarter with data for AstraZeneca medicines featuring in an unprecedented five Presidential Plenary sessions at the two major oncology conferences in September.

    We are highly encouraged by the broad-based underlying momentum we are seeing across our company in 2024, and growth looks set to continue through 2025, providing a solid foundation to deliver on our 2030 ambition.

    Finally, we take the matters in China very seriously. If requested we will fully cooperate with the authorities. We remain committed to delivering innovative life-changing medicines to patients in China."

    Key milestones achieved since the prior results announcement

    • Positive read-outs for Tagrisso plus Orpathys in EGFRm NSCLC with high levels of MET overexpression and/or amplification (SAVANNAH), Calquence in combination with venetoclax, with or without obinutuzumab in previously untreated CLL (AMPLIFY), and the next generation propellant for Breztri. Koselugo in adult patients with NF1-PN (KOMET), Tezspire in severe chronic rhinosinusitis with nasal polyps (WAYPOINT)
    • US approvals for Tagrisso in unresectable, Stage III EGFRm NSCLC (LAURA) and Imfinzi plus chemotherapy in resectable early-stage NSCLC (AEGEAN) and FluMist for self-administration. EU approvals for Imfinzi plus chemotherapy followed by Imfinzi alone in mismatch repair deficient endometrial cancer (DUO-E), Imfinzi plus chemotherapy followed by Lynparza and Imfinzi in mismatch repair proficient endometrial cancer (DUO-E) and Fasenra for EGPA (MANDARA). China approvals for Enhertu in unresectable, locally advanced or metastatic HER2-mutated NSCLC (DESTINY-Lung02, DESTINY-Lung05), Enhertu in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06), and Fasenra for severe eosinophilic asthma (MIRACLE)

    Guidance

    Given the strength of underlying Product Sales and Alliance Revenue, as well as increased confidence in achieving certain sales-based milestones, the Company raises its Total Revenue and Core EPS guidance for FY 2024 at CER.

    Total Revenue is expected to increase by a high teens percentage (previously a mid teens percentage)

    Core EPS is expected to increase by a high teens percentage (previously a mid teens percentage)

    • Other elements of the Income Statement are expected to be broadly in-line with the indications issued in the Company's H1 2024 earnings statement

    The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

    Currency impact

    If foreign exchange rates for October 2024 to December 2024 were to remain at the average rates seen in September 2024, it is anticipated that FY 2024 Total Revenue would incur a low single-digit percentage adverse impact compared to the performance at CER (unchanged from previous guidance), and Core EPS would incur a mid single-digit percentage adverse impact (unchanged from previous guidance). The Company's foreign exchange rate sensitivity analysis is provided in Table 17.

    China

    As previously disclosed, the Company is aware of a number of individual investigations by the Chinese authorities into current and former AstraZeneca employees. To the best of the Company's knowledge, the investigations include allegations of medical insurance fraud, illegal drug importation and personal information breaches. Recently Leon Wang, EVP International and AstraZeneca China President was detained. The Company has not received any notification that it is itself under investigation. If requested, AstraZeneca will fully cooperate with the Chinese authorities.

    Table 1: Key elements of Total Revenue performance in Q3 2024

     

    % Change

     

     

    Revenue type

     

    $m

    Actual %

    CER %

     

    Product Sales

    12,947

    18

    20

     

    Alliance Revenue

     

    559

    48

    50

    * $49m Beyfortus (Q3 2023: $17m)

    * $361m Enhertu (Q3 2023: $266m)

    * $123m Tezspire (Q3 2023: $74m)

    Collaboration Revenue

    59

    (39)

    (40)

    * $56m Beyfortus (Q3 2023: $71m)

    Total Revenue

     

    13,565

    18

    21

     

    Therapy areas

    $m

    Actual %

    CER %

     

    Oncology

    5,569

    19

    22

    * Tagrisso up 14% (17% at CER), Calquence up 24% (25% at CER), Enhertu Total Revenue up 50% (55% at CER)

    CVRM

    3,159

    18

    20

    * Farxiga up 25% (27% at CER), Lokelma up 40% (42% at CER)

    R&I

     

    1,959

    26

    29

    * Breztri up 56% (57% at CER). Saphnelo up 63% (64% at CER), Tezspire up >2x, Symbicort up 27% (31% CER)

    V&I

     

    460

    48

    49

    * Beyfortus Total Revenue up 73% (72% at CER), FluMist up 34% (31% at CER)

    Rare Disease

     

    2,148

    9

    11

    * Ultomiris up 33% (35% at CER), partially offset by decline in Soliris of 22% (18% at CER), Strensiq up 20% (21% at CER) and Koselugo up 37% (39% at CER)

    Other Medicines

     

    270

    (12)

    (8)

     

    Total Revenue

     

    13,565

    18

    21

     

    Regions

     

    $m

    Actual %

    CER %

     

    US

    6,008

    23

    23

     

    Emerging Markets

     

    3,423

    15

    23

     

    - China

    1,671

    15

    15

     

    - Ex-China Emerging Markets

     

    1,752

    16

    31

     

    Europe

     

    2,875

    22

    22

     

    Established RoW

     

    1,260

    (1)

    4

     

    Total Revenue

     

    13,565

    18

    21

     

     

    Key alliance medicines

    • Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited (Daiichi Sankyo) and AstraZeneca, amounted to $2,729m in 9M 2024 (9M 2023: $1,844m).
    • Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $843m in 9M 2024 (9M 2023: $438m).

    Table 2: Key elements of financial performance in Q3 2024

    Metric

    Reported

    Reported change

    Core

    Core

    change

     

    Comments4

    Total Revenue

    $13,565m

    18% Actual 21% CER

    $13,565m

    18% Actual 21% CER

     

    * See Table 1 and the Total Revenue section of this document for further details

    Product Sales Gross Margin

    76%

    -5pp Actual -4pp CER

    81%

    Stable Actual and CER

     

    * Variations in Product Sales Gross Margin can be expected between periods, due to product seasonality (e.g. FluMist and Beyfortus sales are weighted to the second half of the year), foreign exchange fluctuations and other effects

    ‒ Reported Product Sales Gross Margin impacted by PAAGR5 inventory related restructuring charges taken in the quarter

    R&D

    expense

    $3,115m

    21% Actual 21% CER

    $3,068m

    23% Actual 24% CER

     

    + Increased investment in the pipeline

    * Core R&D-to-Total Revenue ratio of 23%

    (Q3 2023: 22%)

    SG&A expense

    $5,143m

    7% Actual 8% CER

    $3,605m

    8% Actual 9% CER

     

    + Market development for recent launches and pre-launch activities

    * Core SG&A-to-Total Revenue ratio of 27%

    (Q3 2023: 29%)

    Other operating income and expense6

    $25m

    -65% Actual -61% CER

    $24m

    -65% Actual -61% CER

     

     

    Operating Margin

    16%

    -1pp Actual Stable CER

    32%

    +1pp Actual +2pp CER

     

    * See commentary above on Gross Margin, R&D, SG&A and Other operating income and expense

    Net finance expense

    $274m

    -6% Actual -15% CER

    $329m

    46% Actual 35% CER

     

    + New debt issued at higher interest rates

    + Higher level of Net debt

    Tax rate

    22%

    +5pp Actual +5pp CER

    19%

    Stable Actual and CER

     

    * Variations in the tax rate can be expected between periods

    EPS

    $0.92

    4% Actual 17% CER

    $2.08

    20% Actual 27% CER

     

    * Further details of differences between Reported and Core are shown in Table 12

    Table 3: Pipeline highlights since prior results announcement

    Event

    Medicine

    Indication / Trial

     

    Event

    Regulatory approvals and other regulatory actions

    Tagrisso

    Unresectable, Stage III EGFRm NSCLC (LAURA)

    Regulatory approval (US)

    Imfinzi

    Primary advanced or recurrent endometrial cancer with mismatch repair deficiency (DUO-E)

    Regulatory approval (EU)

    Imfinzi + Lynparza

    Primary advanced or recurrent endometrial cancer with mismatch repair proficiency (DUO-E)

    Regulatory approval (EU)

    Imfinzi

    Resectable early-stage (IIA-IIIB) NSCLC (AEGEAN)

    Regulatory approval (US)

    Enhertu

    Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06)

    Regulatory approval (CN)

    Enhertu

    Unresectable locally advanced or metastatic HER2m NSCLC (DESTINY-Lung02, DESTINY-Lung05)

    Regulatory approval (CN)

    Fasenra

    EGPA (MANDARA)

    Regulatory approval (US, EU)

    Fasenra

    Fasenra (MIRACLE)

    Regulatory approval (CN)

    FluMist

    Self-administration

    Regulatory approval (US)

    Regulatory submissions

    or acceptances*

    Tagrisso

    EGFRm NSCLC (Stage III

    unresectable) (LAURA)

    Regulatory submission (EU, JP, CN)

    Imfinzi

    Muscle-invasive bladder

    Cancer (NIAGARA)

    Regulatory submission (EU)

    Imfinzi

    NSCLC (neoadjuvant) AEGEAN

    Regulatory submission (JP)

    Imfinzi

    SCLC (limited stage) (ADRIATIC)

    Regulatory submission (US, EU, JP, CN)

    Calquence

    Mantle cell lymphoma (1st-line) (ECHO)

    Regulatory submission (US, EU, JP)

    Calquence

    CLL (ELEVATE-TN)

    Regulatory submission (CN)

    Lynparza

    mCRPC (PROpel)

    Regulatory submission (CN)

    Enhertu

    HER2-low breast cancer

    (2nd-line) (DESTINY-Breast06)

    Regulatory submission (US, EU, JP)

    Wainua

    Hereditary transthyretin-mediated amyloid polyneuropathy (NEURO-TTRansform)

    Regulatory submission (CN)

    Breztri and HFO1234ze

    Moderate to severe COPD

    Regulatory submission (EU)

    Sipavibart

    Prevention of COVID-19

    (SUPERNOVA)

    Regulatory submission (JP)

    Ultomiris

    NMOSD (CHAMPION-NMOSD)

    Regulatory submission (CN)

    Phase III / registrational data readouts and other developments

    Tagrisso + Orpathys

    EGFRm NSCLC with high levels of MET overexpression and/or amplification (SAVANNAH)

    Clinically meaningful ORR

    Calquence fixed duration

    Chronic lymphocytic leukaemia (AMPLIFY)

    Primary endpoint met

    Fasenra

    Eosinophilic chronic rhinosinusitis with nasal polyps (ORCHID)

    Primary endpoint not met

    Tezspire

    Severe chronic rhinosinusitis with nasal polyps (WAYPOINT)

    Primary endpoint met

    Koselugo

    Adults with NF1-PN (KOMET)

    Primary endpoint met

    *US, EU and China regulatory submission denotes filing acceptance

    Upcoming pipeline catalysts

    For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations.html.

    Corporate and business development

    In October 2024, AstraZeneca entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This further strengthens the company's cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease. Under the terms of the agreement, AstraZeneca will receive access to CSPC's pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of cardiovascular disease indications alone or in combination, including with AstraZeneca's oral small molecule PCSK9 inhibitor, AZD0780. CSPC will receive an upfront payment of $100 million from AstraZeneca. CSPC is also eligible to receive up to $1.92 billion for further development and commercialisation milestones plus tiered royalties.

    In October 2024, AstraZeneca entered into an agreement to out-license ALXN1840 (bis-choline tetrathiomolybdate), a drug candidate for Wilson disease to Monopar Therapeutics Inc (Monopar). Monopar will be responsible for all future global development and commercialisation activities. AstraZeneca will have a 9.9% beneficial ownership interest in Monopar upon issuance as well as an upfront cash payment of $4.0 million. AstraZeneca is also eligible to receive milestones and royalties.

    Sustainability highlights

    In September, AstraZeneca had a significant presence at Climate Week NYC and the 79th Session of the UN General Assembly in New York, with a delegation led by Pam Cheng, Executive Vice President of Global Operations and IT and Chief Sustainability Officer and the company's US leadership. A programme of more than 50 engagements with governments, media, NGOs and the private sector focused on the interconnected issues of the climate crisis, health equity and health system resilience and the Company's commitment to contribute to more sustainable, resilient and equitable health systems.

    Conference call

    A conference call and webcast for investors and analysts will begin today, 12 November 2024, at 14:00 UK time. Details can be accessed via astrazeneca.com.

    Reporting calendar

    The Company intends to publish its FY and Q4 2024 results on 6 February 2025.

    To read AstraZeneca's 9M and Q3 2024 Financial Results press release in full including the glossary, please click here.

    _____________________

    1

    Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2024 vs. 2023. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.

    2

    Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 11 and Table 12 in the Financial performance section of this document.

    3

    The calculations for Reported and Core Product Sales Gross Margin exclude the impact of Alliance Revenue and Collaboration Revenue.

    4

    In Table 2, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a ‘+' symbol next to a comment related to the R&D expense indicates that the item resulted in an increase in the R&D spend relative to the prior year.

    5

    Post Alexion Acquisition Group Review. In conjunction with the acquisition of Alexion, the Post Alexion Acquisition Group Review Group initiated a comprehensive review, aimed at integrating systems, structure and processes, optimising the global footprint and prioritising resource allocations and investments. These activities are expected to be substantially complete by the end of 2026.

    6

    Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, continue to be recorded in Other operating income and expense in the Company's financial statements.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241111928553/en/

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients w

      5/7/25 2:30:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

      Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI versus maintenance

      5/2/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • AstraZeneca's Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

      2/6/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/6/25 9:15:27 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/2/25 9:38:38 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care